Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details) € in Millions |
12 Months Ended | |||
|---|---|---|---|---|
Sep. 29, 2023 |
Dec. 31, 2025
EUR (€)
entity
|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Basis of preparation and statement of compliance | ||||
| Number of entities being consolidated | entity | 2 | |||
| Hepalys Pharma, Inc | ||||
| Basis of preparation and statement of compliance | ||||
| Proportion of ownership interest | 15.00% | 15.00% | 15.00% | 15.00% |
| Inventiva Inc. | ||||
| Basis of preparation and statement of compliance | ||||
| Percent of ownership interest | 100.00% | |||
| Non-controlling interest | € | € 0.0 | |||
| X | ||||||||||
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. No definition available.
|
| X | ||||||||||
- Definition The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of entities being consolidated No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|